Retatrutide: The Complete Guide to the Triple Agonist
Retatrutide is the most potent weight loss peptide ever tested in clinical trials. The world's first triple hormone receptor agonist — targeting GLP-1, GIP, and glucagon simultaneously — delivered an average of 28.7% body weight lost (71.2 lbs) in its first Phase 3 trial. It is not yet FDA-approved and cannot be prescribed.
Retatrutide is not FDA-approved and cannot be prescribed.
It is only available through clinical trial enrollment. The information on this page is for educational purposes only — consult a healthcare provider for treatment options.
Key Facts at a Glance
- Drug class
- Triple GIP/GLP-1/Glucagon receptor agonist
- Administration
- Once-weekly subcutaneous injection
- FDA approval
- Not yet approved — Phase 3 trials
- Average loss
- 28.7% body weight (68 wks, TRIUMPH-4)
- Manufacturer
- Eli Lilly
- Expected filing
- Potentially 2027 (pending remaining trials)
- Trial doses
- 1 mg, 4 mg, 8 mg, 9 mg, 12 mg
- Brand name
- None yet (investigational)
Table of Contents
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It activates three incretin and metabolic hormone receptors simultaneously:
- GLP-1Appetite suppression, gastric slowing (shared with semaglutide and tirzepatide)
- GIPEnhanced insulin response, metabolic regulation (shared with tirzepatide)
- GlucagonPromotes fat burning, increases energy expenditure (unique to retatrutide)
No other approved or late-stage medication targets all three pathways. This triple mechanism is why retatrutide has produced more weight loss than semaglutide or tirzepatide in their respective trials.
How Does Retatrutide Work?
Retatrutide combines and extends the mechanisms of its predecessors, adding a third dimension that prior GLP-1 drugs can't match:
GLP-1 Receptor Activation
Suppresses appetite via the hypothalamus, delays gastric emptying, enhances glucose-dependent insulin secretion, and reduces glucagon when blood sugar is high. The same pathways semaglutide and tirzepatide use.
GIP Receptor Activation
Enhances GLP-1's appetite-suppressing effects, improves insulin sensitivity, and contributes additional metabolic regulation. Tirzepatide also uses this pathway, which is why it outperforms semaglutide.
Glucagon Receptor Activation — The Third Dimension
This is what sets retatrutide apart from everything else:
- Increases energy expenditure — glucagon signals the body to burn more energy, even at rest
- Promotes fat oxidation — signals the liver to break down stored fat for fuel
- Reduces liver fat — Phase 2 showed dramatic liver fat reduction (relevant for MASLD/NAFLD)
- Thermogenic effects — may increase basal metabolic rate
Why Three Is Better Than Two
Semaglutide (GLP-1) primarily reduces how much you eat. Tirzepatide (GLP-1 + GIP) does that better. Retatrutide attacks obesity from both sides — it reduces intake AND increases energy expenditure. This dual mechanism is why weight loss curves in retatrutide trials showed no plateau at 48 weeks, unlike semaglutide and tirzepatide where loss typically plateaus around 6–9 months.
Clinical Trial Evidence
Phase 2 Trial (2023)
Published in the New England Journal of Medicine (2023). 338 adults with obesity (no diabetes), randomized across multiple dose arms, 48 weeks.
Results at 24 weeks:
| Dose | Weight Loss at 24 weeks |
|---|---|
| 1 mg | −7.2% |
| 4 mg | −12.9% |
| 8 mg | −17.3% |
| 12 mg | −17.5% |
| Placebo | −1.6% |
Results at 48 weeks (secondary endpoint):
| Dose | Weight Loss at 48 weeks |
|---|---|
| 8 mg | −22.8% |
| 12 mg | −24.2%(best dose) |
| Placebo | −2.1% |
TRIUMPH-4: First Phase 3 Results (December 2025)
The TRIUMPH clinical program enrolled approximately 5,800 participants across 8 Phase 3 trials. TRIUMPH-4 was the first to report results.
Design: Adults with obesity/overweight AND knee osteoarthritis. Duration: 68 weeks. Doses: 9 mg and 12 mg.
| Metric | 9 mg Dose | 12 mg Dose | Placebo |
|---|---|---|---|
| Avg. weight loss | ~22% | 28.7% | ~2% |
| Avg. pounds lost | — | 71.2 lbs | — |
| Placebo-adjusted loss | — | 26.6% | — |
| OA pain reduction | Significant | 75% | — |
These are the strongest weight loss results ever reported in a Phase 3 obesity trial.
Upcoming TRIUMPH Trial Readouts
Seven more Phase 3 trials are expected to report by end of 2026:
| Trial | Population |
|---|---|
| TRIUMPH-1 | Obesity (primary weight loss trial) — most important for FDA approval |
| TRIUMPH-2 | Obesity with type 2 diabetes |
| TRIUMPH-3 | Obesity maintenance |
| TRIUMPH-5 | Obstructive sleep apnea |
| TRIUMPH-6/7/8 | Additional indications and populations |
Current Status: Where Does Retatrutide Stand?
As of March 2026:
- ❌NOT FDA-approved — still in Phase 3 trials
- ✅Phase 3 TRIUMPH-4 showed positive results (December 2025)
- 🔄7 more Phase 3 trials reporting through end of 2026
- 📋FDA filing likely in 2027 at the earliest
How to access retatrutide today
You cannot get a prescription for retatrutide. It's only available through clinical trial enrollment. Research peptide vendors sell it labeled “for research use only” but this carries significant risk — no quality assurance, no medical oversight, and uncertain purity. We strongly recommend waiting for the approved version.
Side Effects & Safety
New Safety Signal: Dysesthesia
TRIUMPH-4 revealed a new side effect not seen in Phase 2 trials: dysesthesia — abnormal sensation including tingling, burning, or unusual perception of touch.
- • 8.8% of patients on 9 mg
- • 20.9% of patients on 12 mg
- • 0.7% on placebo
Dysesthesia events did not appear to cause treatment discontinuation in the trial, but this signal is being closely monitored across remaining TRIUMPH trials. The cause is under investigation — possibly related to the glucagon component or rapid weight loss.
GI Side Effects
GI side effects are more frequent than semaglutide or tirzepatide, likely reflecting the greater potency of the drug:
| Side Effect | Rate (12 mg) |
|---|---|
| Nausea | 43% |
| Diarrhea | 33% |
| Vomiting | 21% |
| Dysesthesia (abnormal sensation) | 20.9% |
| Treatment discontinuation (12 mg) | 18.2% |
| Treatment discontinuation (9 mg) | 12.2% |
Note: some discontinuations in TRIUMPH-4 were in patients with lower BMI who lost weight faster than expected. Phase 3 safety data is still emerging.
Retatrutide vs. Tirzepatide vs. Semaglutide
Note: comparisons are across separate trials, not head-to-head studies. Individual results will vary.
| Retatrutide | Tirzepatide | Semaglutide | |
|---|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Avg. Weight Loss | 28.7% (Phase 3) | 22.5% | 15% |
| Avg. Pounds Lost | 71.2 lbs | ~56 lbs | ~37 lbs |
| FDA Approved | ❌ Phase 3 | ✅ Yes | ✅ Yes |
| Brand Names | — | Mounjaro, Zepbound | Ozempic, Wegovy |
| Unique Benefit | Fat burning + energy expenditure | Dual pathway | Longest track record |
| Weight Plateau | Not observed at 48 wks | ~6–9 months | ~6 months |
| Liver Fat Reduction | Dramatic | Moderate | Some |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
Frequently Asked Questions
When will retatrutide be available?
The earliest realistic timeline for FDA approval is late 2027 or 2028, assuming the remaining Phase 3 trials are positive and Eli Lilly files promptly. Seven more TRIUMPH trials are expected to report by end of 2026.
Is retatrutide better than tirzepatide?
Based on cross-trial comparisons, retatrutide appears significantly more effective — 28.7% vs. 22.5% weight loss in their respective Phase 3 trials. However, there's no direct head-to-head comparison yet. Retatrutide also has a less established safety profile and a new dysesthesia signal.
What is dysesthesia?
Dysesthesia is an abnormal sensation — tingling, burning, or unusual perception of touch. It was reported in up to 20.9% of patients on the highest dose in TRIUMPH-4, compared to 0.7% on placebo. It's a new signal not seen in Phase 2 and is being closely monitored.
Can I buy retatrutide now?
Retatrutide is not FDA-approved and cannot be prescribed. Research peptide vendors sell it labeled 'for research use only,' but this carries significant risk — no quality assurance, no medical oversight, uncertain purity. We strongly advise against this and recommend waiting for the approved version.
Will retatrutide replace tirzepatide?
Possibly for some patients. Eli Lilly makes both drugs and will likely position retatrutide for patients who need more aggressive weight loss than tirzepatide provides. The two may serve different market segments.
What about the higher side effect rates?
Retatrutide's GI side effects are more significant than semaglutide or tirzepatide — nausea in 43% of patients, vomiting in 21%, and 18.2% discontinuation on the highest dose. The dysesthesia signal is also a new concern. These trade-offs will be carefully weighed as more data emerges.
The Bottom Line
Retatrutide is the most powerful weight loss compound ever tested in large-scale clinical trials. The Phase 3 numbers are remarkable: 28.7% average weight loss, 71.2 lbs lost, with ongoing weight reduction at 68 weeks and no plateau in sight.
But it comes with important caveats. The safety profile needs more scrutiny — the dysesthesia signal is new and concerning at 20.9% incidence, and GI side effect rates are meaningfully higher than its predecessors. It remains years away from FDA approval, and the long-term consequences of such dramatic, rapid weight loss are still being studied.
For now, retatrutide represents the frontier of what's possible with obesity pharmacotherapy. If you need a treatment option today, semaglutide and tirzepatide are your FDA-approved options. If the TRIUMPH program continues to deliver, retatrutide may rewrite the playbook entirely — but that conversation is for 2027 at the earliest.
Sources
- 1.Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389(6):514–526.
- 2.Sanyal AJ, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease.” Nat Med. 2024;30:2024–2033.
- 3.Eli Lilly. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” Press release, December 11, 2025.
- 4.Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial.” Lancet. 2023;402(10401):529–544.
- 5.ClinicalTrials.gov. NCT05931367 — TRIUMPH-4.
- 6.“Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2025.